Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Breast Neoplasms × ridaforolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 2 Solid Tumors 1 Recurrence 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Lymphoma 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Advanced Cancers 1

Interventions

Trastuzumab 208 Paclitaxel 167 Cyclophosphamide 138 Docetaxel 111 Capecitabine 103 Letrozole 100 Fulvestrant 93 Doxorubicin 89 Bevacizumab 78 exemestane 67 Anastrozole 67 Carboplatin 66 Lapatinib 62 Tamoxifen 58 palbociclib 49 Albumin-Bound Paclitaxel 49 Taxes 47 Gemcitabine 45 pertuzumab 41 eribulin 40 Radiotherapy 37 Vinorelbine 35 Ado-Trastuzumab Emtansine 35 Everolimus 34 pembrolizumab 32 ixabepilone 32 130-nm albumin-bound paclitaxel 29 pegfilgrastim 24 Magnetic Resonance Spectroscopy 23 Goserelin 23

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01605396 2019-03-25

MK-8669-064

Merck Sharp & Dohme LLC

Phase 2 Completed

80 enrolled 13 charts

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡